Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,589.87
(
0.51%
)
US TECH 100
23,510.80
(
0.65%
)
Dow Jones
46,406.25
(
0.61%
)
Brent Oil
97.83
(
1.37%
)
Bitcoin
70,840.23
(
0.46%
)
News Focus
News Focus
Post# of 257284
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 192179

Saturday, 06/06/2015 4:00:54 PM

Saturday, June 06, 2015 4:00:54 PM

Post# of 257284

AAVL—…if the results show that one-shot isn't going to be enough but the drug otherwise shows it can meaningfully reduce the number of shots needed (compared to Lucentis) and shares tank, I think AAVL could be worth a look.

In other words, if the stocks sells off despite fairly good data, it could become a good buy. Yes, I agree with that :- )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today